Wants to prolong the survival of AML patients by combining two drugs: Professor Dr. Michael Heuser Copyright: MHH / Karin Kaiser
The MHH is looking for subjects with an IDH1 gene mutation for a multicenter study on the combination therapy of two drugs previously used individually against acute myeloid leukemia (AML)
28.04.2023
Acute myeloid leukemia (AML) is a malignant disease in which the precursor cells of the hematopoietic system proliferate uncontrollably. This form of blood cancer is caused by genetic changes in the bone marrow that occur in the course of life. It is therefore mainly older people who are affected. If left untreated, AML leads to death within a few weeks. ...
TO READ THIS ARTICLE, CREATE YOUR ACCOUNT
And extend your reading, free of charge and with no commitment.
